Studies
Blog
Spending Watch
Backfilling Lost Federal Education Funding Will Cost California Dearly
Backfilling Lost Federal Education Funding Will Cost California Dearly Wayne Winegarden February 2025 The erratic actions of the Trump Administration are undoubtedly making it more difficult for states to budget for the upcoming 2026 fiscal year. The knee-jerk reaction from many California politicians is to call for more taxes on ...
Drug Prices
New Brief: ‘Maximum Fair Price’ Policy Would Bring New Costs to Nevada Taxpayers, Put Patient Access to Health Care at Risk
SACRAMENTO – Nevada taxpayers could face millions in new bureaucratic costs and patients will likely see less access to life-saving drugs if state government mandates so-called “Maximum Fair Price” price controls on prescription drugs, finds a new brief released today by the Center for Medical Economics and Innovation at the ...
Business & Economics
Tariffs Harm American Consumers, Manufacturers and the Economy, Warns New Study
SACRAMENTO – Recently enacted and proposed tariffs will have devastating consequences for American families, businesses, and the overall economy, according to a new study by the Pacific Research Institute. The report, authored by economist Dr. Wayne Winegarden, finds that tariffs will lead to higher consumer prices, increased manufacturing costs, and ...
Blog
China and America: The War Over the Panama Canal
READ THE PDF China and America: The War Over the Panama Canal “If the government in China in a conflict tells them to shut down the Panama Canal, they will have to,” said Secretary of State Marco Rubio to SiriusXM’s Megyn Kelly on January 30, referring to Chinese businesses in ...
Drug Innovation
Why Failure-to-Market Claims Are Preempted Under Federal Law
A California appellate court invented out of whole cloth a new and troubling theory of tort liability. Specifically, the court held that drug companies have a duty to develop and bring to market drugs that are supposedly safer and more effective than another, FDA-approved drug the company sells already. The ...
Blog
Will South Korea Survive?
READ THE PDF Will South Korea Survive? On December 27, the National Assembly, South Korea’s unicameral legislature, passed a motion impeaching Acting President Han Duck-soo, the first impeachment of an acting president in the history of the Republic of Korea. Now, nothing less than the continuation of democracy on the ...
Biosimilars
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Blog
Spending Watch
A More Effective Safety Net, Not A Basic Income, Will Help Lift People Out of Poverty
A More Effective Safety Net, Not A Basic Income, Will Help Lift People Out of Poverty Wayne Winegarden and Nikhil Agarwal December 2024 2024 was a good year for proponents of a universal basic income (UBI). Following the 2019 experiment in Stockton, UBI pilot programs are underway across cities in ...
Blog
The Gordon Chang Report–Why China Believes Taiwan Is An Existential Threat
READ THE PDF Why China Believes Taiwan is an Existential Threat “The reunification of the motherland is a historical inevitability,” Xi Jinping proclaimed in his 2024 New Year’s address, referring to Taiwan.[1] China’s annexation of Taiwan as its 34th province, however, is by no means guaranteed. So far, Taiwan—officially the ...
Biosimilars
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
Spending Watch
Backfilling Lost Federal Education Funding Will Cost California Dearly
Backfilling Lost Federal Education Funding Will Cost California Dearly Wayne Winegarden February 2025 The erratic actions of the Trump Administration are undoubtedly making it more difficult for states to budget for the upcoming 2026 fiscal year. The knee-jerk reaction from many California politicians is to call for more taxes on ...
New Brief: ‘Maximum Fair Price’ Policy Would Bring New Costs to Nevada Taxpayers, Put Patient Access to Health Care at Risk
SACRAMENTO – Nevada taxpayers could face millions in new bureaucratic costs and patients will likely see less access to life-saving drugs if state government mandates so-called “Maximum Fair Price” price controls on prescription drugs, finds a new brief released today by the Center for Medical Economics and Innovation at the ...
Tariffs Harm American Consumers, Manufacturers and the Economy, Warns New Study
SACRAMENTO – Recently enacted and proposed tariffs will have devastating consequences for American families, businesses, and the overall economy, according to a new study by the Pacific Research Institute. The report, authored by economist Dr. Wayne Winegarden, finds that tariffs will lead to higher consumer prices, increased manufacturing costs, and ...
China and America: The War Over the Panama Canal
READ THE PDF China and America: The War Over the Panama Canal “If the government in China in a conflict tells them to shut down the Panama Canal, they will have to,” said Secretary of State Marco Rubio to SiriusXM’s Megyn Kelly on January 30, referring to Chinese businesses in ...
Why Failure-to-Market Claims Are Preempted Under Federal Law
A California appellate court invented out of whole cloth a new and troubling theory of tort liability. Specifically, the court held that drug companies have a duty to develop and bring to market drugs that are supposedly safer and more effective than another, FDA-approved drug the company sells already. The ...
Will South Korea Survive?
READ THE PDF Will South Korea Survive? On December 27, the National Assembly, South Korea’s unicameral legislature, passed a motion impeaching Acting President Han Duck-soo, the first impeachment of an acting president in the history of the Republic of Korea. Now, nothing less than the continuation of democracy on the ...
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Spending Watch
A More Effective Safety Net, Not A Basic Income, Will Help Lift People Out of Poverty
A More Effective Safety Net, Not A Basic Income, Will Help Lift People Out of Poverty Wayne Winegarden and Nikhil Agarwal December 2024 2024 was a good year for proponents of a universal basic income (UBI). Following the 2019 experiment in Stockton, UBI pilot programs are underway across cities in ...
The Gordon Chang Report–Why China Believes Taiwan Is An Existential Threat
READ THE PDF Why China Believes Taiwan is an Existential Threat “The reunification of the motherland is a historical inevitability,” Xi Jinping proclaimed in his 2024 New Year’s address, referring to Taiwan.[1] China’s annexation of Taiwan as its 34th province, however, is by no means guaranteed. So far, Taiwan—officially the ...
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
